A Randomized,Controlled Clinical Trial of Continuous Intravenous Pump-ing Recombinant Human Endostatin Focused on First-line Treatment of Advanced Non-small Cell Lung Cancer with Angiostatin Combined with Chemotherapy
Objective To investigate a randomized,controlled clinical trial of continuous intravenous pumping recom-binant human endostatin combined with first-line chemotherapy in the treatment of advanced non-small cell lung can-cer(NSCLC).Methods 150 patients with advanced NSCLC treated from March 2019 to September 2022 in Ya'an People's Hospital were selected as the study objects,and divided into two groups according to the random number table method,75 cases in each group,the chemotherapy group was given conventional first-line chemotherapy regi-men,and the combination group was treated with continuous intravenous pumps focusing on human vascular endothe-lial inhibitors on the basis of the chemotherapy group,the effect of treatment between the two groups was analyzed.Results At the end of treatment,the total effective rate of the combination group was 72.00%higher than that of the chemotherapy group(56.00%),and the difference was statistically significant(χ2=4.167,P<0.05).Cytokeratin 19 frag-ment,carbohydrate antigen 125 and carcinoembryonic antigen in the combination group,were lower than those of the chemotherapy group,and the differences were statistically significant(all P<0.05);and hypoxia inducible factors-1α,vascular endothelial growth factor and angiopoietin-2,were lower than those of the chemotherapy group in the combi-nation group,and the differences were statistically significant(all P<0.05).CD3+,CD4+,CD4+/CD8+ in the combination group were higher than thsoe of the chemotherapy group,and CD8+ was lower than that of the chemotherapy group,and the differences were statistically significant(all P<0.05);the incidence rate of adverse reactions in the two groups was compared,and the difference was not statistically significant(P>0.05).Conclusion Continuous intravenous pump-ing of endostatin combined with first-line chemotherapy is effective in the treatment of advanced NSCLC,which can significantly reduce the levels of serum tumor markers and vascular endothelial factors in patients,improve the im-mune function of the body,enhance the control of tumor cell activity in vivo,and thus improve the clinical efficacy without increasing the adverse reactions.
Continuous intravenous pumpingRecombinant human endostatinChemotherapyLate stageNon-small cell lung cancer
万方数据
维普
